NCT06075615View on ClinicalTrials.gov

A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

September 30, 2024

Primary Completion Date

September 7, 2026

Study Completion Date

September 7, 2026

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

dacomitnib

patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY